Drug Interactions. Stephen Kravcik MD FRCPC Division of General Medicine University of Ottawa

Size: px
Start display at page:

Download "Drug Interactions. Stephen Kravcik MD FRCPC Division of General Medicine University of Ottawa"

Transcription

1 Drug Interactions Stephen Kravcik MD FRCPC Division of General Medicine University of Ottawa

2 Conflicts of Interest None with pharmaceutical industry Consultant with PHAC CADTH CMPA WSIB

3 Clinical Burden of DDIs 3-5% of preventable in-hospital adverse drug reactions Majority are unanticipated and unrecognized until after the occurrence

4 P-glycoprotein Two big players

5 Cytochrome P450

6 Teaching about DDIs Interesting, if you re a nerd Pretty dry otherwise

7

8 DOACs Antibiotics HIV Meds Warfarin Miscellaneous Cool drug AEs

9 DOACS 100 A 57yo woman with severe COPD, on chronic azithromycin, develops A fib and requires OAC. With which DOAC are macrolides safely taken?

10 DOACS 100 None DOAC metabolism is, at least in part, controlled by P-glycoprotein All macrolides are strong PGP inhibitors Therefore, macrolide use will increase all DOAC activity, and may lead to an increase in bleeding Fralick M, Juurlink DN, Marras T. Bleeding associated with coadministration of rivaroxaban and clarithromycin. CMAJ Jun 14;188(9):669-72

11

12

13 DOACS 200 An HIV+ man on Genvoya, which has a strong CYP3A4 inhibitor, is found to have A fib. He has terrible veins and wishes to avoid warfarin use. Which DOAC is safest with a strong inhibitor of CYP450 3A4?

14 DOACS 200 Dabigatran Its is minimally metabolized by any of the cytochromes The other DOACS are significantly metabolized by CYP450, so inhibitors or inducers of these enzymes will have a significant effect on the effectiveness or safety of DOACs But dabigatran is still not terribly safe with HIV Pis as they inhibit Pgp So best change ARVs or use warfarin

15 DOACs 300 Which is least safe with a DOAC when treating a fib: a beta blocker, verapamil or digoxin?

16 DOACs 300 Verapamil is a strong inhibitor of PGP, and may lead to an increased risk of bleeding if on a DOAC.

17 DOACs 400 Which anticonvulsant is safest with a rivaroxaban or apixaban: phenytoin, carbamazepine or valproic acid?

18 DOACs 400 Valproic acid Phenytoin and carbamazepine are strong inducers of CYP450 3A4 and inducers of PGP, so may dramatically reduce DOAC effectiveness If these are required, use warfarin: affected by CYP450 but can follow the INR

19 DOACs 500 Is amiodarone safe with DOACS?

20 DOACs 500 Moderate CYP3A4 and mild-mod P- gp inhibitor Dabi levels increase 40% Use with caution with any DOAC

21 Antibiotics 100 Which antituberculous drug is the most potent known CYP450 inducer?

22 Antibiotics 100 Rifampin Potential substrates: All calcium channel blockers All benzos except for lorazepam, oxazepam and temazepam Statins (not much with pravastatin) Estrogens Apixaban, rivaroxaban, warfarin

23 Antibiotics 200 A 65 yo female with dyspepsia, who loves her TUMS, who has not seen a doctor in years, fails treatment of a sensitive gram- UTI with cipro. Why?

24 Antibiotics 200 Tums and any other di- or tri-valent cations may bind quinolones and reduce their absorption Tums et al should be given at least 2 hours before or 6 hours after a quinolone dose The same holds for iron, calcium supps and phosphate binders Do not take with dairy products Also happens with tetracyclines

25 Antibiotics 300 A depressed middle aged bodybuilder on citalopram receives linezolid for an MRSA cellulitis. He develops myoclonus and hyperreflexia. Why?

26 Antibiotics 300 Linezolid use may lead to serotonin syndrome if taken with drugs that increase serum serotonin levels: Antidepressants Analgesics SSRIs Paroxetine Sertraline Fluoxetine Fluvoxamine Citalopram Escitalopram SNRIs Venlafaxine Duloxetine Mirtazapine Tricyclic antidepressants Amitriptyline Clomipramine Desipramine Doxepin Imipramine Nortriptyline Protriptyline NRIs Trazodone Nefazodone MAOIs Tranylcypromine Phenelzine Selegiline Tramadol Meperidine Methadone Dextromethorphan Dextropropoxyphene Pentazocine Antituberculosis Isoniazid Anxiolytics Buspirone Hypnotics l-tryptophan Migraine Sumatriptan and other triptans Stimulants Amphetamine and derivatives Antineoplastic Procarbazine Dopamine agonists Bromocriptine Illicit psychotropics Cocaine Lysergic acid diethylamide Ecstasy Methylenedioxyamphetamine N-methyldiethanolamine Herbals 3,4-Methylenedioxymethamphetamine St. John's Wort (Hypericum perforatum) Ginseng (Panax ginseng)

27 Antibiotics 400 A 55 yo male with ALL, on methotrexate, becomes neutropenic when treated for a GAS pharyngitis. Why?

28 Antibiotics 400 Penicillins block the tubular secretion of methotrexate and can lead to a significant increase in plasma MTX levels, leading to greater hepatic, renal and bone marrow toxicity of MTX NSAIDs cause renal efferent arteriolar vasoconstriction and relative renal hypoperfusion. This can lead to MTX bio-accumulation and toxicity.

29 Antibiotics 500 What happens when you mix meropenem and valproic acid?

30 Antibiotics 500 Valproic acid levels plummet The nature of the interaction is uncertain Increasing valproic acid doses will frequently not overcome the reaction and puts the patient at risk of toxicity when the meropenem is stopped

31 HIV Meds 100 Which two HIV antiretroviral components are potent P4503A4 inhibitors?

32 HIV Meds 100 Ritonavir and cobicistat Ritonavir in Norvir, Kaletra Cobicistat in Stribild, Genvoya, Prezcobix

33 HIV Meds 100

34 HIV Meds 200 Which inhaled corticosteroid is safest for someone on ritonavir

35 HIV Meds 200 The safest ICS is Qvar (beclomethasone) Virtually all other inhaled (oral and nasal) CS are P450-metabolized Many case reports of hypercortisolism when taken with potent P450 inhibitors

36 HIV Meds 300 Which calcium channel blocker is safest in someone taking Genvoya?

37 None. HIV Meds 300. All CCBs are CYP450 3A4 metabolized, and their bioavailability dramatically increased when used with ritonavir (Norvir, Kaletra) or cobicistat (Prezcobix, Stribild, Genvoya)

38 HIV Meds 400 Which is the safest statin with ritonavir? Atorvastatin Simvastatin Lovastatin Pravastatin Rosuvastatin

39 HIV Meds 400 Which is the safest statin with ritonavir? Atorvastatin limit to 20 mg/day Simvastatin DO NOT USE Lovastatin DO NOT USE Pravastatin no concerns Rosuvastatin - limit to 10 mg/day

40 HIV Meds 500 Which of these significantly interacts with ritonavir/cobicistat? Diazepam Sildenafil Ergotamine Ticagrelor

41 HIV Meds 500 All do Diazepam (only safe BDZs are lorazepam, temazepam and oxazepam) Sildenafil (AUC increases 4x; same with other PDE 5 inhibitors) Ergotamine (absolute CI) Ticagrelor (AUC increase 7x)

42 Warfarin 100 Is warfarin pharmacology straightforward?

43 . Warfarin 100 Not a chance Warfarin is a racemic mixture of its R-isomer (less potent) and S-isomer (more potent). S-warfarin is metabolized primarily by the CYP 2C9 isoenzyme whereas R-warfarin is metabolized by CYP 1A2 and 3A4. Depending on the dominant isoenzyme inhibited by the interacting drug, the effect on warfarin may or may not be clinically significant. Consequently, drugs that impact CYP 2C9 metabolism can be expected to have a disproportionate effect on the INR There are numerous agents, such as metronidazole, trimethoprim/sulfamethoxazole (TMP/SMX), and amiodarone, that are commonly prescribed to older individuals that inhibit the CYP 2C9 pathway These medications, when used in conjunction with warfarin have significant effects on the INR and bleeding risk. In addition, while warfarin clearance is not affected by renal dysfunction, serum levels of interacting drugs (such as ciprofloxacin or TMP/SMX) may increase with renal dysfunction, enhancing the interaction. Absorption is affected by gut flora, whih is affected by antoibiotics

44 Warfarin 200 Is there an oral antibiotic that is free of the potential to alter warfarin absorption or metabolism?

45 Warfarin 200 No Almost all antibiotics can potentiate the effects of warfarin by: Alteration of intestinal flora that produce vitamin K Inhibition or induction of cytochrome P450 Unless the INR can be monitored every other day, ciprofloxacin, macrolides, metronidazole and TMP-SMX generally should not be prescribed to patients who are taking warfarin

46 Warfarin 300 Is acetaminophem safe with warfarin?

47 Warfarin 300 No As few as seven 325-mg tablets of acetaminophen can lead to increased warfarn effect. The proposed mechanism is the inhibition of CYP450 by acetaminophen resulting in decreased metabolism of warfarin.

48 Warfarin 400 Do statins affect warfarin-related anticoagulation?

49 Warfarin 400 Yes. Statins may inhibit CYP450 metabolism of warfarin displace warfarin from its binding site on albumin. Unanticipated elevated INR with warfarin has been reported with concomitant use of fluvastatin, lovastatin, simvastatin and atorvastatin

50 Warfarin 500 What proportion of patients on warfarin for atrial fibrillation are taking herbal supps?

51 [48] Warfarin 500 ~50% In one study of patients prescribed warfarin for chronic atrial fibrillation patients taking no herbal medications or only 1 herbal < 4 times per week were more likely to have PT-INR values within the optimal therapeutic range (2.0 to 3.0) compared to those taking > 1 type of herbal 4 times per week (58.1% vs 51.1%, P = 0.046) H.T. Chan, L.T. So, S.W. Li, C.W. Siu, C.P. Lau, H.F. Tse. Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation. J Cardiovasc Pharmacol, 58 (1) (2011), pp

52 Miscellaneous 100 What does grapefruit juice do to drug metabolism?

53 Miscellaneous 100 A lot: Grapefruit contains various furanocoumarins that inhibit CYP3A4, potentially resulting in increases in some drug levels. Grapefruit also weakly inhibits intestinal cell P-gp, decreasing the efflux of some absorbed drugs back into the gut lumen. Organic anion transporting polypeptide (OATP) is another transporter system affected by grapefruit. Unlike with CYP3A4 and P-gp, drugs handled by OATP may have decreased absorption when taken with grapefruit, possibly leading to decreased efficacy.

54 Miscellaneous 200 What does omeprazole do to clopidogrel?

55 Miscellaneous 200 It reduces its effectiveness Clopidogrel s anti-platelet activity is entirely the effect of an active metabolite The active metabolite is formed as the result of clopidogrel metabolism by CYP2C19 Omeprazole inhibits CYP2C19 activity.

56 Miscellaneous 300 How do NSAIDs affect lithium therapy?

57 Miscellaneous 300 They reduce renal clearance of lithium and therefore may increase serum levels Both NSAIDs and diuretics may lead to increased proximal resorption of lithium It is recommended that lithium doses be reduced 50% when starting an NSAID or diuretic.

58 Miscellaneous 400 Why are nitrates to be used with caution with phosphodiesterase inhibitors?

59 Miscellaneous 400 Sildafenil and other phosphodiesterase inhibitors potentiate (double) the effect of nitrates All nitrates become NO in vivo NO promote conversion of GTP to cgmp, which leads to smooth muscle relaxation and venodilation cgmp is metabolized/inactivated by phosphodiesterase 5; inhibition leads to greater and more prolonged vasodilation, leading to potentially severe hypotension No nitrates within 24 hours of sildenafil or vardenafil, or within 36 hours of tadalafil

60 Miscellaneous 500 Why must tramadol be used with caution in patients taking SSRIs?

61 Miscellaneous 500 Tramadol exerts its analgesic action through binding of an opiate receptor as well as inhibition of SE and NE uptake Concomitant SSRI use has been reported to lead to the development of serotonin syndrome

62 Cool Drug AEs 100 Name four drugs that can cause this:

63 Cool Drug AEs 100 Pulmonary fibrosis (predominantly lower lobes) Nitrofurantoin Amiodarone Methotrexate Bleomycin Cyclophosphamide Numerous other case reports (see Pneumotox website

64 Cool Drug AEs 200 What is this and what caused it?

65 Cool Drug AEs 200 Flagellate hyperpigmentation from bleomycin Prevalence of flagellate hyperpigmentation in those treated with bleomycin may be as high as 20%. flagellate hyperpigmentation usually fades over a period of several months after the cessation of the medication.

66 Cool Drug AEs 300 What is this and what caused it?

67 Cool Drug AEs 300 HIV lipodystrophy Lipoatrophy associated with thymidine analogue nucleoside RTIs like AZT, d4t Lipohypertrophy less clearly associated with any class; possibly associated with older PIs Metabolic abnormalities (impaired glucose tolerance, dyslipidemia) associated with fat deposition, fat thinning, AZT, d4t, PIs

68 What drug? Cool Drug AEs 400

69 Cool Drug AEs 400 Blue-grey skin hyperpigmentation from amiodarone Occurs in 1-3% of patients on long term low dose amiodarone ( mg/d) May resolve with lower dose or discontinuation (but may take 1+ year)

70 Cool Drug AEs 500 She s bluish but not dyspneic.

71 Methemoglobinemia Causes: sulphonamides Dapsone Local anaesthetics Metocopramide nitrates Cool Drug AEs 500

72 Things to Remember Look for DDIs: When using a DOAC When using anticonvulsants When using macrolides When using amiodarone When dealing with a patient on meds for HIV When dealing with a patient on meds for TB

73

74 Thank you

Self Assessment Question 1

Self Assessment Question 1 Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1 Self

More information

Drug Interactions for the Emergency Physician. Lisa Thurgur

Drug Interactions for the Emergency Physician. Lisa Thurgur Drug Interactions for the Emergency Physician Lisa Thurgur Objectives Why we should care about drug-drug interactions Cases How can we avoid these interactions Short list of culprit drugs Drug-Drug Interaction

More information

Drug Interactions Year 2 Clinical Pharmacology

Drug Interactions Year 2 Clinical Pharmacology 1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful

More information

Drug Interactions Year 2 Clinical Pharmacology

Drug Interactions Year 2 Clinical Pharmacology 1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and

More information

Cytochrome P450 Drug Interaction Table Flockhart Table

Cytochrome P450 Drug Interaction Table Flockhart Table Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A

More information

Drug Interactions: Let me count the ways

Drug Interactions: Let me count the ways : Let me count the ways President: PRN Associates, Ltd. Continuing Education in Pharmacology Tucson, AZ Objectives At the conclusion of this continuing education lesson, the participant will be able to:

More information

Who remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?

Who remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do? Drug Interactions: Things that go BOOM! Who remembers Terfenadine? Once daily non-sedating anti-histamine Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates A strange thing happened

More information

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Antibiotic Class Interacting Drug Comment Penicillins Methotrexate Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Cephalosporins Cefaclor Cefixime Cefuroxime Cephalexin Cefazolin* Ceftriaxone*

More information

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention

More information

The Case of Libby Zion and Dangerous Drug Interactions

The Case of Libby Zion and Dangerous Drug Interactions The Case of Libby Zion and Dangerous Drug Interactions J.R.White, PA, PharmD I. MAOI and Meperidine Libby Zion 18 yo female Rx c phenelzine (Nardil) Meperidine given for shaking chills Outcome Death Libby

More information

To understand the formulary process from the hospital perspective

To understand the formulary process from the hospital perspective Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels

More information

MORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)

MORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone) Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories

More information

Drug Interactions: Mechanisms and Potential Clinical Outcomes

Drug Interactions: Mechanisms and Potential Clinical Outcomes : Mechanisms and Potential Clinical Outcomes Alan P. Agins, Ph.D. President PRN Associates, Ltd Continuing Medical Education Tucson, AZ Objectives Specify the two major clinical outcomes of drug interactions

More information

CATEGORIES: QUIZ 2. Drugs Categories. 1. What drug subcategory often ends with the suffix -asone?

CATEGORIES: QUIZ 2. Drugs Categories. 1. What drug subcategory often ends with the suffix -asone? CATEGORIES: QUIZ 2 Drugs Categories 1. What drug subcategory often ends with the suffix -asone? a. Alpha blockers b. Corticosteroids c. Calcium channel blockers d. Beta blockers e. ACE inhibitors 2. What

More information

HYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.

HYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist. Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published

More information

90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR

90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90

More information

Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None

Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past

More information

Duragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist

Duragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have

More information

Antidepressant Pharmacology An Overview

Antidepressant Pharmacology An Overview Figure 1. Antidepressant Pharmacology An Overview Source: NEJM 2005;353:1819-34 Figure 2. 1 Figure 3: Antidepressant Pharmacology pictures: Weak inhibition Bupropion NOTE: CYP enzymes noted are those inhibited

More information

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole

More information

Objectives. Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner

Objectives. Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner Wendy L. Wright, MS, ANP-BC, FNP-BC, FAANP, FAAN, FNAP Family Nurse Practitioner Owner - Wright & Associates Family Healthcare Amherst,

More information

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review

More information

Pharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP

Pharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions

More information

COMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS. Dan Malone, RPh, PhD Professor University of Arizona

COMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS. Dan Malone, RPh, PhD Professor University of Arizona COMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS Dan Malone, RPh, PhD Professor University of Arizona Disclosures I, Daniel Malone, have no financial relationships to disclose

More information

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir

More information

Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE

Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an

More information

Drug drug interactions highlighting P450 Cytochromes. Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017

Drug drug interactions highlighting P450 Cytochromes. Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017 Drug drug interactions highlighting P450 Cytochromes Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017 Financial Disclosures and Conflicts I have no financial disclosures nor conflicts concerning

More information

Xartemis XR (oxycodone / acetaminophen extended release)

Xartemis XR (oxycodone / acetaminophen extended release) RATIONALE FOR INCLUSION IN PA PROGRAM Background Xartemis XR is a combination of oxycodone and acetaminophen in a dosage formulation to deliver both immediate pain relief, in less than an hour, and extended-release

More information

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S. BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

A clinical guide to managing drugdrug interactions in antiretroviral therapy

A clinical guide to managing drugdrug interactions in antiretroviral therapy HIVPA 2008, 6 th June 2008 HIV Pharmacology and TDM B Marta Boffito MD PhD St. Stephen s Centre Chelsea and Westminster Hospital, London A clinical guide to managing drugdrug interactions in antiretroviral

More information

PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX

PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual

More information

Clinical Case Discussion of Drug-Drug Interactions: Minefield or Molehill? David Back

Clinical Case Discussion of Drug-Drug Interactions: Minefield or Molehill? David Back Clinical Case Discussion of Drug-Drug Interactions: Minefield or Molehill? David Back University of Liverpool UK David Back University of Liverpool Rome December 2012 Clinical case: patient characteristics

More information

Nucynta IR. Nucynta IR (tapentadol immediate-release) Description

Nucynta IR. Nucynta IR (tapentadol immediate-release) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta IR Page: 1 of 9 Last Review Date: December 8, 2017 Nucynta IR Description Nucynta IR (tapentadol

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS WHOPAR part 4 January 2017 Section 6 updated: March 2017 SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 30 WHOPAR part 4 January 2017 Section 6 updated: March 2017 1. NAME OF THE MEDICINAL PRODUCT * 2. QUALITATIVE

More information

Drug Therapy Following Bariatric Surgery

Drug Therapy Following Bariatric Surgery Drug Therapy Following Bariatric Surgery Linda F. McElhiney PharmD, RPh, MSP, FIACP, FACA, FASHP, DPLA Compounding Pharmacist Indiana University Health Disclosures Dr. McElhiney declare(s) no conflicts

More information

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM RATIONALE FOR INCLUSION IN PA PROGRAM Background Tramadol is a centrally acting synthetic opioid analgesic used to treat moderate to moderately severe chronic pain in adults. Along from analgesia, tramadol

More information

QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT

QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-17-237-L01-T 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for

More information

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free

More information

Initiation Guide. Images not actual size.

Initiation Guide. Images not actual size. Initiation Guide Images not actual size. INDICATIONS AND USAGE SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data

Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data pubs.acs.org/crt Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data Nina Isoherranen,* Justin D. Lutz, Sophie

More information

Levorphanol. Levorphanol Tartrate. Description

Levorphanol. Levorphanol Tartrate. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol

More information

Mental Health DNA Insight WHITE PAPER

Mental Health DNA Insight WHITE PAPER Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,

More information

OXYCODONE IR (oxycodone)

OXYCODONE IR (oxycodone) RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,

More information

Killer Drug Interactions. Karen Curzio Rodeghiero, PharmD, BCPS Clinical Pharmacist, Emergency Medicine Piedmont Athens Regional

Killer Drug Interactions. Karen Curzio Rodeghiero, PharmD, BCPS Clinical Pharmacist, Emergency Medicine Piedmont Athens Regional Killer Drug Interactions Karen Curzio Rodeghiero, PharmD, BCPS Clinical Pharmacist, Emergency Medicine Piedmont Athens Regional Disclosure I have no financial interests or relationships to disclose Primum

More information

Butrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017

Butrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Butrans Page: 1 of 9 Last Review Date: September 15, 2017 Butrans (buprenorphine patch) Description

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS Section 6 updated: March 2017 SUMMARY OF PRODUCT CHARACTERISTICS 1 Section 6 updated: March 2017 1. NAME OF THE MEDICINAL PRODUCT Ritonavir Tablets 100 mg * 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Belbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description

Belbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2017 Belbuca (buprenorphine buccal film)

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize

More information

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions

More information

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Meperidine Page: 1 of 7 Last Review Date: September 15, 2017 Meperidine Description Demerol (meperidine

More information

Drugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD

Drugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be

More information

RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY

RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d

More information

Anti-Depressant Medications

Anti-Depressant Medications Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change

More information

GUIDANCE FOR LEAPFROG HOSPITAL SURVEY PARTICIPATING HOSPITALS CLINICAL DECISION SUPPORT RELATED TO THE CPOE EVALUATION TOOL

GUIDANCE FOR LEAPFROG HOSPITAL SURVEY PARTICIPATING HOSPITALS CLINICAL DECISION SUPPORT RELATED TO THE CPOE EVALUATION TOOL GUIDANCE FOR LEAPFROG HOSPITAL SURVEY PARTICIPATING HOSPITALS CLINICAL DECISION SUPPORT RELATED TO THE CPOE EVALUATION TOOL CPOE Evaluation Tool Guidance Last Updated 04/01/2018 1 INTRODUCTION To fully

More information

CARDIAC REHABILITATION PROGRAMME:- MEDICATION

CARDIAC REHABILITATION PROGRAMME:- MEDICATION CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to

More information

BELBUCA (buprenorphine buccal film)

BELBUCA (buprenorphine buccal film) RATIONALE FOR INCLUSION IN PA PROGRAM Background Belbuca is indicated for the management of chronic pain severe enough to require daily, aroundthe-clock, long-acting opioid treatment for which alternative

More information

Jolene R. Bostwick, PharmD, BCPS, BCPP Clinical Associate Professor Associate Chair, Department of Clinical Pharmacy University of Michigan College

Jolene R. Bostwick, PharmD, BCPS, BCPP Clinical Associate Professor Associate Chair, Department of Clinical Pharmacy University of Michigan College Jolene R. Bostwick, PharmD, BCPS, BCPP Clinical Associate Professor Associate Chair, Department of Clinical Pharmacy University of Michigan College of Pharmacy Clinical Pharmacist in Psychiatry University

More information

eview Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP yright t for Sale or Commercial Distribution

eview Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP yright t for Sale or Commercial Distribution Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP Presented at the University of Saskatchewan s 4th Annual Peter and Anna Zbeetnoff Memorial Drug Therapy Decision-Making Conference,

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Norvir 80 mg/ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of oral solution contains 80 mg of ritonavir.

More information

Hysingla ER. Hysingla ER (hydrocodone bitartrate) Description

Hysingla ER. Hysingla ER (hydrocodone bitartrate) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.38 Subject: Hysingla ER Page: 1 of 9 Last Review Date: September 15, 2017 Hysingla ER Description

More information

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100

More information

Morphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),

Morphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone), Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine IR Drug Class Page: 1 of 11 Last Review Date: December 8, 2017 Morphine IR Hydromorphone

More information

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also

More information

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications. Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically

More information

SMOKING AND DRUG INTERACTIONS

SMOKING AND DRUG INTERACTIONS Medicines Information Centre Pharmacy Department UK Medicines Information SMOKING AND DRUG INTERACTIONS Introduction Smoking rates are significantly higher among people with mental health problems. It

More information

Volume 4; Number 5 May 2010

Volume 4; Number 5 May 2010 Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated

More information

Antidepressant Treatment of Depression

Antidepressant Treatment of Depression Antidepressant Treatment of Depression PLEASE REFER TO INTEGRATED CARE PATHWAY FOR INFORMATION RELATING TO THE OVERALL MANAGEMENT OF DEPRESSION SSRI s are first choice agents because they are as effective

More information

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 8 Last Review Date: September 15, 2017 Embeda Description Embeda (morphine

More information

Psychotropic Drug Interactions Over the past 2 decades:

Psychotropic Drug Interactions Over the past 2 decades: Psychotropic Drug Interactions Over the past 2 decades: Treatment options: Several and non- therapies Increasing number of psychotropic s Increased risk of adverse outcomes Overwhelming information on

More information

Levorphanol. Levorphanol Tartrate. Description

Levorphanol. Levorphanol Tartrate. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Current Drugs: Drug-Drug Interactions

Current Drugs: Drug-Drug Interactions Slide 1 Current Drugs: Drug-Drug Interactions David Back University of Liverpool UK David Back University of Liverpool May 2013 Toxicity HCV med Comed Reduced Efficacy The major effect of DAAs is to increase

More information

Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml

Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml Abbott Virology 100 Abbott Park Road Abbott Park, IL 60064 KALETRA 100/25 mg tablets NDC #0074-0522-60 Dear Healthcare Provider: Introducing a new strength of KALETRA (lopinavir/ritonavir): 100/25 mg tablets

More information

Quetiapine Case 1 Warfarin Jose de Leon, MD

Quetiapine Case 1 Warfarin Jose de Leon, MD Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,

More information

Duragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019

Duragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Duragesic patch Page: 1 of 9 Last Review Date: November 30, 2018 Duragesic patch Description Duragesic patch (fentanyl

More information

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US

More information

Belbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016

Belbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2016 Belbuca (buprenorphine buccal film)

More information

12/9/2015. Drug Interactions. Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc.

12/9/2015. Drug Interactions. Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc. Drug Interactions Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc. Boston, MA, USA December 10, 2015 1 1 Overview Epidemiology and Categories of Drug

More information

- how many anti-depressant pills were prescribed to patients in years 2011/12/13

- how many anti-depressant pills were prescribed to patients in years 2011/12/13 NHS Wet Kent Clinical Commiioning Group Our Ref: FOI.14.WK0196 RE: FREEDOM OF INFORMATION REQUEST Thank you for your requet for information under the Freedom of Information Act 2000 received on 25 February

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

Evaluation of Drug-Drug Interactions FDA Perspective

Evaluation of Drug-Drug Interactions FDA Perspective Evaluation of Drug-Drug Interactions FDA Perspective Kellie Schoolar Reynolds, Pharm.D. Deputy Director Division of Clinical Pharmacology IV Office of Clinical Pharmacology Office of Translational Sciences

More information

4.3 Antidepressants (ADDs) BNF Section 4.3

4.3 Antidepressants (ADDs) BNF Section 4.3 4.3 Antidepressants (ADDs) BNF Section 4.3 The aim of this guidance is to provide prescribing guidance and highlight good practice. It is not intended to be a comprehensive practice treatment guideline.

More information

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe

More information

Duragesic patch. Duragesic patch (fentanyl patch) Description

Duragesic patch. Duragesic patch (fentanyl patch) Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 9 Last Review Date: September 15, 2017 Duragesic patch Description Duragesic patch (fentanyl

More information

Original Research Article Actual and Potential Drug Interactions Associated with Methadone

Original Research Article Actual and Potential Drug Interactions Associated with Methadone Blackwell Publishing IncMalden, USAPMEPain Medicine1526-23752007 Blackwell Publishing Ltd? 200793315344Review Article Actual and Potential Drug Interactions Associated with MethadoneWeschules et al. PAIN

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

Drug Interactions: Definition

Drug Interactions: Definition Drug Interactions Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Center Pharmacy Department National Institutes of Health December 9, 2010 Drug Interactions:

More information

Study Guidelines for Quiz #1

Study Guidelines for Quiz #1 Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing

More information

Guidelines on Choice and Selection of Antidepressants for the Management of Depression

Guidelines on Choice and Selection of Antidepressants for the Management of Depression Guidelines on Choice and Selection of Antidepressants for the Management of Depression 1. Introduction This guidance should be considered as part of a stepped care approach in the management of depressive

More information

patient group direction

patient group direction ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society

Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Coumadin (Warfarin) Does this medication need ongoing monitoring of blood clotting times? Yes.

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist

More information

Interactions Between Herbal Medicines and Prescribed Drugs

Interactions Between Herbal Medicines and Prescribed Drugs REVIEW ARTICLE Drugs 2009; 69 (13): 1777-1798 0012-6667/09/0013-1777/$55.55/0 ª 2009 Adis Data Information BV. All rights reserved. Interactions Between Herbal Medicines and Prescribed Drugs An Updated

More information

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen

More information

DNA & Allergen Compatibility Report

DNA & Allergen Compatibility Report DNA & Allergen Compatibility Report REPORT FOR: JOHN W. DOE 11.21.2017 John W. Doe Personal Profile CURRENT MEDICATIONS: FOOD: Advil 07.11.2017 Clopidogrel 07.23.2017 Doxepin 09.04.2017 Fluoxetine 09.17.2017

More information

There is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.

There is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin. amciclovir amciclovir + Probenecid Probenecid is predicted to increase the exposure to penciclovir, the active metabolite of famciclovir, possibly resulting in increased adverse effects. Evidence is limited

More information

NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing

NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158

More information